Merino, Jordi http://orcid.org/0000-0001-8312-1438
Dashti, Hassan S. http://orcid.org/0000-0002-1650-679X
Sarnowski, Chloé http://orcid.org/0000-0002-6090-7099
Lane, Jacqueline M. http://orcid.org/0000-0001-6101-2855
Todorov, Petar V. http://orcid.org/0000-0003-4835-0643
Udler, Miriam S. http://orcid.org/0000-0003-3824-9162
Song, Yanwei
Wang, Heming http://orcid.org/0000-0002-1486-7495
Kim, Jaegil
Tucker, Chandler
Campbell, John
Tanaka, Toshiko
Chu, Audrey Y.
Tsai, Linus http://orcid.org/0000-0002-0134-6949
Pers, Tune H. http://orcid.org/0000-0003-0207-4831
Chasman, Daniel I. http://orcid.org/0000-0003-3357-0862
Rutter, Martin K.
Dupuis, Josée http://orcid.org/0000-0003-2871-3603
Florez, Jose C. http://orcid.org/0000-0002-1730-9325
Saxena, Richa http://orcid.org/0000-0003-2233-1065
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK040561, DK105072, DK078616, DK078616, DK110550, DK107859, DK105072)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL007901)
Novo Nordisk (NNF16OC0021496, NNF16OC0021496)
American Diabetes Association (1-18-INI-14)
Article History
Received: 3 September 2019
Accepted: 12 July 2021
First Online: 23 August 2021
Competing interests
: A.Y.C. is currently employed by Merck Research Laboratories. M.K.R. reports receiving research funding from Novo Nordisk, consultancy fees from Novo Nordisk and Roche Diabetes Care and modest owning of shares in GlaxoSmithKline. All other authors declare no competing interests.